SC

Shaan C. Gandhi

VP at Pfizer

Cambridge, Massachusetts

Overview 

Shaan C. Gandhi is the Head of Strategic Partnerships at Pfizer Ignite, with notable achievements including serving as Vice President at Pfizer, investing in various healthcare companies like Kyverna Therapeutics and CAMP4 Therapeutics. He holds an MD from Harvard Medical School, an MBA from Harvard Business School, and has been involved in numerous healthcare and biotechnology boards. Gandhi's career highlights include his role as Vice President at Pfizer and his involvement in investing in successful healthcare companies like Kyverna Therapeutics and CAMP4 Therapeutics.

Work Experience 

  • Vice President and Head of Strategic Partnerships, Pfizer Ignite

    2023 - Current

    Pfizer Ignite is a new end-to-end offering for biotech partners that leverages Pfizer’s resources, scale and expertise to amplify and accelerate innovation from preclinical R&D through the development lifecycle. Learn more at www.pfizerignite.com.

Pfizer is a biopharmaceutical company that provides affordable access to safe, effective medicines and health care services.

Raised $32,000,000,000.00 from Starboard Value.

  • Independent Board Member

    2023

1910 Genetics is a biotechnology company integrating AI, computation, and biological automation to improve drug development.

Raised $26,650,000.00 from Accenture Ventures.

  • Board Member

    2020 - 2023

    Acquired by Eli Lilly (NYSE: LLY) August 2023, formerly NASDAQ: DICE

  • Board Member

    2020 - 2023

    NASDAQ: VIGL

Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.

Raised $180,000,000.00 from Sanofi.

  • Board Member

    2022 - 2022

    NASDAQ: KYTX

Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases.

Raised $170,000,000.00 from Northpond Ventures, Gilead Sciences, CAM Capital, Westlake Village BioPartners, LYFE Capital, Insight Partners, Bain Capital Life Sciences, RTW Investments, Vida Ventures and GordonMD Global Investments.

  • Board Member

    2022 - 2022

Transition Bio provides condensate technology for drug discovery and diagnostics.

Raised $63,265,426.00 from Bristol-Myers Squibb, Northpond Ventures, Taiho Ventures, Magnetic Ventures and Lifeforce Capital.

  • Board Member

    2021 - 2022

StrideBio is a gene therapy company that develops genetic medicines with curative potential for patients with devastating conditions.

Raised $97,200,000.00 from Northpond Ventures, CaaS Capital Management, Takeda Ventures, Sarepta Therapeutics, Alexandria Venture Investments, Novo Holdings, UCB Ventures, UF Innovate Ventures, Pontifax and Octagon Capital Advisors.

  • Board Member

    2021 - 2022

CAMP4 Therapeutics is a biotechnology company that uses RNA to restore healthy gene expression.

Raised $190,000,000.00 from The Kraft Group, Enavate Sciences, Andreessen Horowitz, Gaingels, Polaris Partners, Northpond Ventures and 5AM Ventures.

  • Board Member

    2021 - 2022

  • Board Member

    2021 - 2022

Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat life-threatening diseases.

Raised $134,000,000.00 from Northpond Ventures, Alexandria Venture Investments, Sectoral Asset Management, Cormorant Asset Management, OrbiMed, Mass General Brigham Ventures and Aisling Capital.

Articles About Shaan C.

Relevant Websites